• Publications
  • Influence
An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea.
There is a critical need for interdisciplinary translational research to connect Dyspnea mechanisms with clinical treatment and to validate dyspnea measures as patient-reported outcomes for clinical trials.
Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines.
Substantial new evidence that pulmonary rehabilitation is beneficial for patients with COPD and other chronic lung diseases and several areas of research provide opportunities for future research that can advance the field and make rehabilitative treatment available to many more eligible patients in need.
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes.
The results indicate that dyspnea can receive a direct clinical rating that provides important information not disclosed by customary physiologic tests.
ACSM's guidelines for exercise testing and prescription
Health appraisal, risk assessment, and safety of exercise exercise testing exercise prescription and training.
Evaluation of clinical methods for rating dyspnea.
The results show that the BDI, MRC scale, and OCD provide significantly related measures of Dyspnea, and the clinical ratings of dyspnea correlate significantly with physiologic parameters of lung function; and breathlessness may be related to the pathophysiology of the specific respiratory disease.
Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.
It is concluded that FSC improved lung function and reduced the severity of dyspnea compared with individual components and placebo.
Efficacy of salmeterol xinafoate in the treatment of COPD.
These collective data support the use of salmeterol as first-line bronchodilator therapy for the long-term treatment of airflow obstruction in patients with COPD.
The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease.
Subjects with moderate to severe COPD did not benefit from treatment with infliximab and the impact of inflIXimab on malignancy risk in patients with COPD needs to be further elucidated.
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
Indacaterol was an effective once-daily bronchodilator and was at least as effective as tiotropium in improving clinical outcomes for patients with COPD.
Outcomes for COPD pharmacological trials: from lung function to biomarkers
The American Thoracic Society/European Respiratory Society jointly created a Task Force on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform the chronic